Hormonal

Teriparatide

Also known as: Forteo, PTH 1-34

FDA Approved
Share:

Key Facts: Teriparatide

Category
Hormonal
FDA Status
FDA Approved
Clinical Status
FDA Approved - Osteoporosis
Administration
Subcutaneous injection daily
Typical Dose
20 mcg daily
Frequency
Once daily
Duration
Maximum 2 years (lifetime limit due to osteosarcoma concern)
Also Known As
Forteo, PTH 1-34

Mechanism of Action

Teriparatide activates the PTH/PTHrP type 1 receptor, a G-protein-coupled receptor on bone cells, switching on the adenylate cyclase/protein kinase A pathway and, secondarily, phospholipase C signaling. The timing is everything: a brief once-daily spike preferentially stimulates osteoblasts, the cells that lay down new bone, and tips the remodeling balance toward formation. Continuously high PTH, by contrast, favors osteoclast-driven bone breakdown, which is why chronic hyperparathyroidism weakens bone while intermittent teriparatide strengthens it. The result is increased bone mineral density and, importantly, improved bone microarchitecture and strength, not just denser-looking scans.

Research Summary

Teriparatide is backed by a landmark randomized human trial, not preclinical extrapolation. The Fracture Prevention Trial by Neer and colleagues in the New England Journal of Medicine in 2001 enrolled postmenopausal women with prior vertebral fractures and showed teriparatide cut new vertebral fractures by about 65 percent and nonvertebral fragility fractures by roughly half over a median 19 months. Those results drove its 2002 FDA approval as the first anabolic osteoporosis agent. Early rat studies had flagged osteosarcoma at high lifetime doses, prompting an initial boxed warning and 2-year use limit, but a completed 15-year post-marketing surveillance study found no such human signal, and the FDA removed both the boxed warning and the cumulative-use cap in 2020. It is well-established medicine for severe osteoporosis, typically reserved for high fracture risk given its cost and injection burden.

Trial Progress:FDA Approved
Pre
I
II
III
IV
FDA

Dosing Information

FDA Approved·Human clinical trials completed, FDA approved

Typical Dosing

Community experience

Common Dose

20 mcg daily

Range

20 mcg daily

Frequency

Once daily

FDA-approved PTH analog for osteoporosis. Max 2 years treatment. Injection in thigh or abdomen.

Research Dosing

Scientific studies

FDA-approved dosing

Doses from Studies

Duration

Maximum 2 years (lifetime limit due to osteosarcoma concern)

Administration

Subcutaneous injection daily

Timing & Administration

Best Time to Take

Morning or as directed

Follow recommended protocol

Food Recommendation

With or without food

Why This Timing?

Timing may vary based on individual response and goals. Consistency is generally more important than specific timing.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • Joint pain (10%)
  • Nausea
  • Headache
  • Dizziness
  • Leg cramps
  • Injection site reactions
  • Orthostatic hypotension
  • Hypercalcemia
  • BOXED WARNING: Osteosarcoma risk - limit to 2 years
  • FDA approved (Forteo)

References

Research This Peptide Further

Frequently Asked Questions

What does Teriparatide do?

Teriparatide (brand name Forteo) is the first 34 amino acids of human parathyroid hormone, made by recombinant DNA, and it was the first drug approved that actually builds new bone rather than just slowing its loss. FDA-approved in 2002 for osteoporosis at high fracture risk, it is given as a once-daily self-injection. The counterintuitive trick is that the same hormone which strips calcium from bone when high around the clock instead grows bone when delivered in a short daily pulse.

How does Teriparatide work?

Teriparatide activates the PTH/PTHrP type 1 receptor, a G-protein-coupled receptor on bone cells, switching on the adenylate cyclase/protein kinase A pathway and, secondarily, phospholipase C signaling. The timing is everything: a brief once-daily spike preferentially stimulates osteoblasts, the cells that lay down new bone, and tips the remodeling balance toward formation. Continuously high PTH, by contrast, favors osteoclast-driven bone breakdown, which is why chronic hyperparathyroidism weakens bone while intermittent teriparatide strengthens it. The result is increased bone mineral density and, importantly, improved bone microarchitecture and strength, not just denser-looking scans.

Is Teriparatide FDA approved?

Yes, Teriparatide is FDA approved. FDA Approved - Osteoporosis

What are the side effects of Teriparatide?

Reported side effects include: Joint pain (10%), Nausea, Headache, Dizziness, Leg cramps. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Teriparatide?

Community-reported common dose: 20 mcg daily (Once daily). Range: 20 mcg daily. Administration: Subcutaneous injection daily. Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with Teriparatide or used in similar applications.

Oxytocin

FDA

Oxytocin is a 9-amino-acid hormone made in the hypothalamus, famous as the chemistry behind labor contractions, breastfeeding, and social bonding. As an injectable drug it is FDA-approved to induce labor and control postpartum bleeding, but the intranasal 'love hormone' versions sold for trust, anxiety, and autism are experimental and the human results are genuinely mixed. The hype runs well ahead of the evidence.

Hormonal

Gonadorelin

FDA

Gonadorelin is a synthetic copy of natural GnRH (gonadotropin-releasing hormone), a 10-amino-acid peptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) that tells the pituitary to release LH and FSH. It is FDA-approved for evaluating pituitary function and has historical use in inducing ovulation. In the peptide world it is mostly used off-label to keep the testes working during testosterone replacement, and the catch is that timing matters enormously: pulse it and you stimulate, give it continuously and you shut the system down.

Hormonal

Leuprolide

FDA

Leuprolide (brand name Lupron) is a synthetic GnRH agonist, a modified peptide about 20 times more potent than natural GnRH, and it is FDA-approved for advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. The clever part is counterintuitive: it works by overstimulating the GnRH system so hard that the pituitary shuts down sex hormone production. It is a real, long-established prescription drug, not a research peptide, and it carries meaningful side effects from the low-hormone state it creates.

Hormonal

Desmopressin

FDA

Desmopressin (dDAVP) is a synthetic tweak of the natural hormone vasopressin, redesigned to keep the water-retaining effect while dropping most of the blood-pressure effect. It is a long-established FDA-approved drug used for central diabetes insipidus, bedwetting and nocturia, and certain bleeding disorders like von Willebrand disease and mild hemophilia A. This is settled medicine, not an experimental peptide, and its main real-world danger is straightforward: it can drop your blood sodium dangerously low if you drink too much fluid on it.

Hormonal

Octreotide

FDA

Octreotide is a synthetic eight-amino-acid mimic of the natural hormone somatostatin, the body's main 'off switch' for hormone secretion. It shuts down excess growth hormone, so it is a frontline FDA-approved drug for acromegaly, and it also tames the flushing and diarrhea of hormone-secreting carcinoid and other neuroendocrine tumors. This is real, approved medicine with decades of clinical data behind it, sold as Sandostatin (injectable, since 1988), Sandostatin LAR (monthly depot), and Mycapssa (oral capsule, approved 2020).

Hormonal

Lanreotide

FDA

Lanreotide is an eight-amino-acid somatostatin analog, a close cousin of octreotide, given as a long-acting deep-injection gel (Somatuline Depot/Autogel) usually once a month. It is FDA-approved for acromegaly and for gastroenteropancreatic neuroendocrine tumors, and it carries an approval for carcinoid syndrome. It is established prescription medicine, not an experimental compound.

Hormonal

Want updates on Teriparatide research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.